Some 30,000 Americans contracted pancreatic cancer last year, and, 29,900 (99.7%) of them succumbed to their disease. Pancreatic cancer accounts for approximately 25% of all Gl neoplasms, and is by far the one with the worst prognosis. Indeed, with a mean life expectancy from diagnosis of only 3 months, this disease represents one of the grimmest fronts of the War on Cancer. Currently there is only one FDA approved drug for the treatment of this disease, Gemcitabine, a nucleoside antimetabolite. Unfortunately, multiple phase III trials using single agent Gemcitabine at the FDA approved dose and schedule have shown, (i) a consistent response rate of only <10%; (ii) median survival of approximately 6 months; and (iii) one year survival rates of <20%. Recent phase II data, however, have suggested that the rate of delivery of gemcitabine can have a favorable impact on the median survival. Consequently, our overarching hypothesis is that the amount and rate of Gemcytabine uptake and anababolism in the tumor will correlate with that particular individual patient response. Validating this assumption is crucial in order to be able to customize dose and administration rate and regimens to each individual patient. To test this hypothesis we propose to apply localized Fluorine Magnetic Resonance Spectroscopy (19F-MRS) at ultra high magnetic field of 7 Tesla, for non invasive, in vivo monitoring the drug and its active anabolic by product di-fluoro, de-oxycytadine tri-phosphate (dFdCTP). ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA111911-04
Application #
7409167
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Zhang, Huiming
Project Start
2005-07-01
Project End
2010-04-30
Budget Start
2008-05-01
Budget End
2010-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$421,996
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Fleysher, Roman; Fleysher, Lazar; Kirov, Ivan et al. (2009) Retrospective correction for T1-weighting bias in T2 values obtained with various spectroscopic spin-echo acquisition schemes. Magn Reson Imaging 27:1410-9
Fleysher, Roman; Fleysher, Lazar; Liu, Songtao et al. (2009) On the voxel size and magnetic field strength dependence of spectral resolution in magnetic resonance spectroscopy. Magn Reson Imaging 27:222-32
Fleysher, Roman; Fleysher, Lazar; Liu, Songtao et al. (2008) TriTone: a radiofrequency field (B1)-insensitive T1 estimator for MRI at high magnetic fields. Magn Reson Imaging 26:781-9
Fleysher, Lazar; Fleysher, Roman; Liu, Songtao et al. (2008) Voxel-shift and interpolation for hadamard-encoded MR images. Magn Reson Med 60:524-35
Fleysher, Roman; Fleysher, Lazar; Gonen, Oded (2008) The optimal MR acquisition strategy for exponential decay constants estimation. Magn Reson Imaging 26:433-5
Goelman, Gadi; Liu, Songtao; Fleysher, Roman et al. (2007) Chemical-shift artifact reduction in Hadamard-encoded MR spectroscopic imaging at high (3T and 7T) magnetic fields. Magn Reson Med 58:167-73